Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$157.28M+15.6%$151.39M+19.2%$144.17M+21.9%$138.91M+26.5%$136.03M+37.8%
$42.28M+24.3%$40.02M+25.6%$36.8M+27.5%$35.63M+35.3%$34.01M+37.8%
$199.56M+17.4%$191.41M+20.5%$180.97M+23.0%$174.54M+28.2%$170.04M+37.8%
$199.56M+17.4%$191.41M+20.5%$180.97M+23.0%$174.54M+28.2%$170.04M+37.8%
-$199.56M-17.4%-$191.41M-20.5%-$180.97M-23.0%-$174.54M-28.2%-$170.04M-37.8%
$23.55M-1.7%$23.61M-5.6%$23.73M+3.8%$23.84M+17.4%$23.95M+36.4%
-$176.01M-20.5%-$167.8M-25.4%-$157.24M-26.5%-$150.7M-30.1%-$146.09M-38.0%
-$1.67-7.7%-$1.64-13.1%-$1.58-5.3%-$1.550.0%-$1.550.0%
-$1.67-7.7%-$1.64-13.1%-$1.58-5.3%-$1.550.0%-$1.550.0%
420.5M+12.2%408.5M+11.2%398M+17.5%386.3M+25.3%374.9M+34.8%
420.5M+12.2%408.5M+11.2%398M+17.5%386.3M+25.3%374.9M+34.8%
-$176.66M-22.0%-$167.54M-25.5%-$157.59M-28.3%-$149.45M-28.4%-$144.82M-36.0%
$23.55M-1.7%$23.61M-5.6%$23.73M+3.8%$23.84M+17.4%$23.95M+36.4%
-$629K$281K
$23.55M-1.7%$23.61M-5.6%$23.73M+3.8%$23.84M+17.4%$23.95M+36.4%
-$199.56M-17.4%-$191.41M-20.5%-$180.97M-23.0%-$174.54M-28.2%-$170.04M-37.8%
-$197.5M-17.6%-$189.37M-20.8%-$178.88M-23.2%-$172.45M-28.4%-$167.95M-38.1%
-$197.5M-17.6%-$189.37M-20.8%-$178.88M-23.2%-$172.45M-28.4%-$167.95M-38.1%
-$199.56M-17.4%-$191.41M-20.5%-$180.97M-23.0%-$174.54M-28.2%-$170.04M-37.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Edgewise Therapeutics, Inc.'s income statement data come from?
Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.